Guangdong BPC raw material receiving records, Kaiser repacking irregularities cited in warning letters.
Executive Summary
GUANGDONG PHARMACEUTICAL RECEIVING RECORDS ARE "INNACCURATE" and "incomplete" for the factory in Guangzhou City, China, FDA told the bulk pharmaceutical company in a March 10 FDA warning letter. The agency documented recordkeeping insufficiencies for raw material receiving records and finished product distribution records during an inspection of the Chinese BPC facility from Sept. 5 through Sept. 7.